



Ref: FOIA Reference 2024/25-278

Date: 12th August 2024

Email foi@uhn.nhs.uk

Dear Sir/Madam

I am writing to acknowledge receipt of your email dated 26th July 2024 requesting information under the Freedom of Information Act (2000) regarding asthma

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 I am conducting analysis on the treatment of severe asthma in secondary care and kindly request your help.

I would be grateful if you could respond with the number of patients treated with specific medicines between the start of April 2024 to the end of June 2024, or the latest three-month period for which data is available. Please include data for all hospitals in the Health Board.

How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	
1.2 Dupilumab (Dupixent)	
1.3 Mepolizumab (Nucala)	
1.4 Omalizumab (Xolair)	
1.5 Reslizumab (Cinqaero)	
1.6 Tezepelumab (Tezspire)	

A1 See below:

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	92
1.2 Dupilumab (Dupixent)	78
1.3 Mepolizumab (Nucala)	77
1.4 Omalizumab (Xolair)	35
1.5 Reslizumab (Cinqaero)	0
1.6 Tezepelumab (Tezspire)	46

Q2 How many patients were treated for severe asthma, atopic dermatitis, CRwNP and other indications with the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic rhinosinusitis with nasal polyps (CRwNP)	Atopic Dermatitis	Other
2.1 Benralizumab (Fasenra)		N/A	N/A	N/A
2.2 Dupilumab (Dupixent)				
2.3 Mepolizumab (Nucala)			N/A	
2.4 Omalizumab (Xolair)			N/A	
2.5 Reslizumab (Cinqaero)		N/A	N/A	N/A
2.6 Tezepelumab (Tezspire)		N/A	N/A	N/A

A2 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic rhinosinusitis with nasal polyps (CRwNP)	Atopic Dermatitis	Other
2.1 Benralizumab (Fasenra)	13	N/A	N/A	N/A
2.2 Dupilumab (Dupixent)	<5	0	0	74
2.3 Mepolizumab (Nucala)	6	0	N/A	71
2.4 Omalizumab (Xolair)	<5	0	N/A	34
2.5 Reslizumab (Cinqaero)	0	N/A	N/A	N/A
2.6 Tezepelumab (Tezspire)	7	N/A	N/A	N/A

Q3 How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024?

Name of medicine	Respiratory departments	Dermatology departments	Other
3.1 Benralizumab (Fasenra)			
3.2 Dupilumab (Dupixent)			
3.3 Mepolizumab (Nucala)			
3.4 Omalizumab (Xolair)			
3.5 Reslizumab (Cinqaero)			
3.6 Tezepelumab (Tezspire)			

A3 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved,

and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5

This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

Name of medicine	Respiratory departments	Dermatology departments	Other
3.1 Benralizumab (Fasenra)	92	0	0
3.2 Dupilumab (Dupixent)	10	68	0
3.3 Mepolizumab (Nucala)	75	0	<5
3.4 Omalizumab (Xolair)	<5	0	33
3.5 Reslizumab (Cinqaero)	0	0	0
3.6 Tezepelumab (Tezspire)	46	0	0

Q4 How many patients were treated for Asthma the following medicines in the 3 months between the start of April 2024 and end of June 2024?
Please answer this question for ICS-LABA combination medicines e.g. Symbicort, Seretide and other branded or generic versions of the combination.

Name of combination medicine	Pack strength	Number of patients
4.1 Fluticasone with salmeterol	All strengths	
4.2 Fluticasone with salmeterol	500mcg fluticasone / 50mcg salmeterol	
4.3 Budesonide with formoterol	All strengths	
4.4 Budesonide with formoterol	400mcg budesonide / 12mcg formoterol	
4.5 Fluticasone with vilanterol	All strengths	
4.6 Fluticasone with vilanterol	184mcg fluticasone / 22mcg vilanterol	
4.7 Beclometasone with formoterol	All strengths	
4.8 Beclometasone with formoterol	200mcg beclomethasone / 6mcg formoterol	
4.9 Fluticasone with formoterol	All strengths	
4.10 Fluticasone with formoterol	250mcg fluticasone / 10mcg formoterol	

- A4 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers as being <5
This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.

Name of combination medicine	Pack strength	Number of patients
4.1 Fluticasone with salmeterol	All strengths	47
4.2 Fluticasone with salmeterol	500mcg fluticasone / 50mcg salmeterol	<5
4.3 Budesonide with formoterol	All strengths	31
4.4 Budesonide with formoterol	400mcg budesonide / 12mcg formoterol	<5
4.5 Fluticasone with vilanterol	All strengths	14
4.6 Fluticasone with vilanterol	184mcg fluticasone / 22mcg vilanterol	9
4.7 Beclometasone with formoterol	All strengths	142
4.8 Beclometasone with formoterol	200mcg beclomethasone / 6mcg formoterol	38
4.9 Fluticasone with formoterol	All strengths	17
4.10 Fluticasone with formoterol	250mcg fluticasone / 10mcg formoterol	10

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.

Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

Yours,



Rachel Montinaro
Data Security and Protection Manager - Records